These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 31608215)

  • 1. TIPS Is Not Associated with a Higher Risk of Developing HCC in Cirrhotic Patients: A Systematic Review and Meta-analysis.
    Chen B; Pang L; Chen HB; Wu DB; Wang YH; Chen EQ
    J Clin Transl Hepatol; 2019 Sep; 7(3):232-237. PubMed ID: 31608215
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and efficacy of transjugular intrahepatic portosystemic shunt combined with palliative treatment in patients with hepatocellular carcinoma.
    Luo SH; Chu JG; Huang H; Yao KC
    World J Clin Cases; 2019 Jul; 7(13):1599-1610. PubMed ID: 31367619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt: a retrospective case-control study.
    De Santis A; Iegri C; Kondili L; Riggio O; Salvatori FM; Catalano C; Di Martino M; Bassanelli C; Lupo M; Lucatelli P; Attili AF
    Dig Liver Dis; 2014 Aug; 46(8):726-30. PubMed ID: 24893685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk Factors for Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt in Patients with Hepatocellular Carcinoma and Portal Hypertension.
    Yao J; Zuo L; An G; Yue Z; Zhao H; Wang L; Liu F
    J Gastrointestin Liver Dis; 2015 Sep; 24(3):301-7. PubMed ID: 26405702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension.
    Qiu B; Zhao MF; Yue ZD; Zhao HW; Wang L; Fan ZH; He FL; Dai S; Yao JN; Liu FQ
    World J Gastroenterol; 2015 Nov; 21(43):12439-47. PubMed ID: 26604651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with variceal bleeding in liver cirrhosis: outcomes and predictors in a prospective cohort study.
    Qi X; He C; Guo W; Yin Z; Wang J; Wang Z; Niu J; Bai M; Yang Z; Fan D; Han G
    Liver Int; 2016 May; 36(5):667-76. PubMed ID: 26235541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of a transjugular intrahepatic portosystemic shunt on the diagnosis of hepatocellular cancer.
    Wong K; Ozeki K; Kwong A; Patel BN; Kwo P
    PLoS One; 2018; 13(12):e0208233. PubMed ID: 30592722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients with cirrhosis and bare-stent TIPS may have increased risk of hepatocellular carcinoma.
    Bañares R; Núñez O; Escudero M; Fernández C; Vaquero J; Beceiro I; Echenagusía A; Clemente G; Santos L
    Hepatology; 2005 Mar; 41(3):566-71. PubMed ID: 15726654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of transjugular intrahepatic portosystemic shunt in the management of portal vein thrombosis: a systematic review and meta-analysis.
    Valentin N; Korrapati P; Constantino J; Young A; Weisberg I
    Eur J Gastroenterol Hepatol; 2018 Oct; 30(10):1187-1193. PubMed ID: 30074506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transjugular intrahepatic portosystemic shunt in combination with or without variceal embolization for the prevention of variceal rebleeding: a meta-analysis.
    Qi X; Liu L; Bai M; Chen H; Wang J; Yang Z; Han G; Fan D
    J Gastroenterol Hepatol; 2014 Apr; 29(4):688-96. PubMed ID: 24117967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Balloon-occluded retrograde transvenous obliteration versus transjugular intrahepatic portosystemic shunt for treatment of gastric varices due to portal hypertension: A meta-analysis.
    Wang YB; Zhang JY; Gong JP; Zhang F; Zhao Y
    J Gastroenterol Hepatol; 2016 Apr; 31(4):727-33. PubMed ID: 26637789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transjugular Intrahepatic Portosystemic Shunt for Acute Variceal Bleeding: A Meta-analysis.
    Qi X; Jia J; Bai M; Guo X; Su C; García-Pagán JC; Han G; Fan D
    J Clin Gastroenterol; 2015 Jul; 49(6):495-505. PubMed ID: 25127113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TIPS versus endoscopic therapy for variceal rebleeding in cirrhosis: A meta-analysis update.
    Zhang H; Zhang H; Li H; Zhang H; Zheng D; Sun CM; Wu J
    J Huazhong Univ Sci Technolog Med Sci; 2017 Aug; 37(4):475-485. PubMed ID: 28786052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transjugular Intrahepatic Portosystemic Shunt for Portal Hypertension in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
    Qiu B; Li K; Dong X; Liu FQ
    Cardiovasc Intervent Radiol; 2017 Sep; 40(9):1372-1382. PubMed ID: 28488102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemokine (C-X-C motif) ligand 11 levels predict survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt.
    Berres ML; Lehmann J; Jansen C; Görtzen J; Meyer C; Thomas D; Zimmermann HW; Kroy D; Schumacher F; Strassburg CP; Sauerbruch T; Trautwein C; Wasmuth HE; Trebicka J
    Liver Int; 2016 Mar; 36(3):386-94. PubMed ID: 26212075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparision between portosystemic shunts and endoscopic therapy for prevention of variceal re-bleeding: a systematic review and meta-analysis.
    Zhou GP; Sun LY; Wei L; Qu W; Zeng ZG; Liu Y; Jiang YZ; Zhu ZJ
    Chin Med J (Engl); 2019 May; 132(9):1087-1099. PubMed ID: 30913064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt.
    Berres ML; Asmacher S; Lehmann J; Jansen C; Görtzen J; Klein S; Meyer C; Strunk HM; Fimmers R; Tacke F; Strassburg CP; Trautwein C; Sauerbruch T; Wasmuth HE; Trebicka J
    J Hepatol; 2015 Feb; 62(2):332-9. PubMed ID: 25457205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted puncture of left branch of intrahepatic portal vein in transjugular intrahepatic portosystemic shunt to reduce hepatic encephalopathy.
    Luo SH; Chu JG; Huang H; Zhao GR; Yao KC
    World J Gastroenterol; 2019 Mar; 25(9):1088-1099. PubMed ID: 30862997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic and splanchnic endothelin-1 plasma levels in liver cirrhosis before and after transjugular intrahepatic portosystemic shunt (TIPS).
    Nolte W; Ehrenreich H; Wiltfang J; Pahl K; Unterberg K; Kamrowski-Kruck H; Schindler CG; Figulla HR; Buchwald AB; Hartmann H; Ramadori G
    Liver; 2000 Feb; 20(1):60-5. PubMed ID: 10726962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transjugular intrahepatic portosystemic shunt as a bridge to non-hepatic surgery in cirrhotic patients with severe portal hypertension: a systematic review.
    Lahat E; Lim C; Bhangui P; Fuentes L; Osseis M; Moussallem T; Salloum C; Azoulay D
    HPB (Oxford); 2018 Feb; 20(2):101-109. PubMed ID: 29110990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.